Ligand Pharmaceuticals Incorporated

Total Valuation

Ligand Pharmaceuticals Incorporated carries a market capitalization of 5.95B, placing it among publicly traded companies globally. Its enterprise value stands at 6.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Ligand Pharmaceuticals Incorporated currently has 19.92M shares outstanding.

Valuation Ratios

Ligand Pharmaceuticals Incorporated trades at a trailing price-to-earnings ratio of 31.75. The price-to-sales ratio is 21.55, and the price-to-book ratio stands at 6.51.

Enterprise Valuation

On an enterprise value basis, Ligand Pharmaceuticals Incorporated trades at an EV/EBITDA multiple of 45.54 and an EV/FCF ratio of 40.71. The EV/Sales ratio of 20.85 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 60.51 provides insight into valuation relative to core operating earnings.

Financial Position

Ligand Pharmaceuticals Incorporated maintains a current ratio of 31.18, meaning it holds 31.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.94, indicating elevated leverage, while an interest coverage ratio of 21.49 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Ligand Pharmaceuticals Incorporated posts a return on equity of 21.96 and a return on invested capital of 5.64.

Taxes

Over the trailing twelve months, Ligand Pharmaceuticals Incorporated has paid 40.74M in income taxes, reflecting an effective tax rate of 17.12.

Stock Price Statistics

Ligand Pharmaceuticals Incorporated's stock has gained approximately 65.12696% over the past 52 weeks. The 50-day moving average sits at 292.54, while the 200-day moving average is 246.42.

Income Statement

Over the trailing twelve months, Ligand Pharmaceuticals Incorporated generated 290.54M in revenue and converted that into 197.22M in net income, yielding earnings per share of 9.45. EBITDA reached 133.01M, while operating income came in at 100.10M.

Balance Sheet

Ligand Pharmaceuticals Incorporated holds 1.37B in cash and equivalents against 1.13B in total debt, resulting in a net debt position of 119.89M. Total book value stands at 967.52M, with working capital of 1.41B providing operational flexibility.

Cash Flow

Ligand Pharmaceuticals Incorporated produced 131.71M in operating cash flow over the past twelve months. After subtracting -11.96M in capital expenditures, free cash flow totaled 119.76M - equivalent to 6.04 per share.

Margins

Ligand Pharmaceuticals Incorporated operates with a gross margin of 95.43, reflecting its pricing power and cost economics. The operating margin of 34.45 and net profit margin of 67.88 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Ligand Pharmaceuticals Incorporated's most recent stock split took place on November 2, 2022 with a 1000:1603 split ratio.

Scores

Ligand Pharmaceuticals Incorporated posts an Altman Z-Score of 4.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.